INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
The DOI matches its Crossref record; 523 of the 536 references it cites were found in a registry or an index.
Abstract
In Brief Background: Intravitreal injection (IVI) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment. The indications and therapeutic agents are reviewed in this study. Methods: A search of the English, German, and Spanish language MEDLINE database was conducted. A total of 654 references spanning the period through early 2008 were individually evaluated. Results: The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment. Intravitreal injection has been used to deliver several types of pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, anticancer agents, gas, antivascular endothelial growth factor, and several others. The goal of this review is to provide a detailed description of the properties of numerous therapeutic agents that can be delivered through IVI, potential complications of the technique, and recommendations to avoid side effects. Conclusion: The IVI technique is a valuable tool that can be tailored to the disease process of interest based on the pharmacological agent selected. This review provides the reader with a comprehensive summary of the IVI technique and its multitude of uses. Intravitreal injection has been used to deliver numerous pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, antineoplastic agents, gas, antivascular endothelial growth factor, and others. In this review, we describe the properties of many intravitreal therapeutic agents, the technique of intravitreal injection, complications, recommendations to avoid side effects, and future trends.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although rates of intraocular inflammation related to intravitreal injection remain relatively low, the overall burden on patients remains a key concern with millions of injections performed every year [85].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [85]
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Effects of cytochalasin and phalloidin on actin.
Cooper, J. A. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.4.1473 · Cited by 2,009
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Research works printed but not linked: 9
- Komoto, 1912, Ueber Glaskorperwaschung bei unheilbarer Glaskorperblutung., KIin Monatsbl Augenheilkd, 50, 265
- Lowenstein, 1912, Uber Glaskorperersatz: 1.Teil: Experimentelle Untersuchungen., Albrecht von Graefes Arch Ophthalmol, 80, 500
- Zirm, 1925, Ein Beitrag zur Glaskorperabsaugung., Klin Monatsbl Augenheilkd, 75, 730
- Kucers, 1979, The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 3rd ed.
- Smith, 2001, Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease., Arthritis Rheum, 45, 252, 10.1002/1529-0131(200106)45:3<252::aid-art257>3.0.co;2-5 · doi:10.1002/1529-0131(200106)45:3<252::aid-art257>3.0.co;2-5
- Rosenfeld, 2006, Ranibizumab: phase III clinical trial results., Ophthalmol Clin North Am, 19, 361
- Case, 1985, Clearance of intravitreal 3H-fluorouracil., Ophthalmic Surg, 16, 378
- Pillat, 1956, The aging of the retina., Trans Am Acad Ophthalmol Otolaryngol, 60, 206
- Dominguez, 1985, Cirugia precoz y ambulatoria del desprendimento de retina. (Spanish)., Arch Soc Esp Oftalmol, 48, 47
Cited by
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
“Novel ocular drug-delivery technologies such as nanoformulations, implants, and other ocular devices allow enhanced drug residence time at the target tissue along with improvements in pharmacological response (Peyman et al., 2009).”
BackgroundDrug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
Patel, S. R., Berezovsky, D. E., McCarey, B. E., Zarnitsyn, V., Edelhauser, H. F., & Prausnitz, M. R. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9872 · Cited by 241
Liposomes for intravitreal drug delivery: A state of the art
Bochot, A., & Fattal, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.019 · Cited by 227
“Frequent administration of drugs via this route can lead to endophthalmitis, damage to lens, retinal detachment and hemorrhage [2,7,12,13].”
BackgroundDossarps, D., Bron, A. M., Koehrer, P., Aho-Glélé, L. S., Creuzot-Garcher, C., Berthon, L., Maftouhi, Q.-E., Bakhti, A., Conrath, J., Le Mer, Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.013 · Cited by 184
“More than 1million IVT injections were performed in the United States in 2009.(1) IVT injections may induce complications, including endophthalmitis, retinal detachment, and cataract.”
BackgroundMinimally invasive microneedles for ocular drug delivery
Thakur Singh, R. R., Tekko, I., McAvoy, K., McMillan, H., Jones, D., & Donnelly, R. F. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1218460 · Cited by 171
Liposomes and nanotechnology in drug development: focus on ocular targets
Honda, M., Asai, Oku, Araki, Tanaka, & Ebihara (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s30725 · Cited by 157
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Solid implantable devices for sustained drug delivery
Magill, E., Demartis, S., Gavini, E., Permana, A. D., Thakur, R. R. S., Adrianto, M. F., Waite, D. T., Glover, K., Picco, C. J., Korelidou, A., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114950 · Cited by 161
Advances in ocular drug delivery: emphasis on the posterior segment
Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.935338 · Cited by 142
“However, it is important to note that the occurrence of these complications is low and with practiced techniques, rate of incidence is minimal [7].”
BackgroundSurvey of Intravitreal Injection Techniques Among Retinal Specialists in the United States
Green-Simms, A. E., Ekdawi, N. S., & Bakri, S. J. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.08.039 · Cited by 142
Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle
Jung, J. H., Chiang, B., Grossniklaus, H. E., & Prausnitz, M. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.001 · Cited by 135
“Standard SCS injections, and intravitreal injections, in humans are just 50 μL [57].”
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: The Importance of Viridans Streptococci
Chen, E., Lin, M., Cox, J., & Brown, D. M. (2011) · Retina · doi:10.1097/iae.0b013e318221594a · Cited by 119
Protein delivery for retinal diseases: From basic considerations to clinical applications
Sanharawi, M. E., Kowalczuk, L., Touchard, E., Omri, S., de Kozak, Y., & Béhar‐Cohen, F. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.001 · Cited by 116
“Particularly anti-VEGF therapies are injected in the vitreous repeatedly to reduce CNV leakage (Peyman et al., 2009).”
BackgroundMaulvi, F. A., Shetty, K. H., Desai, D. T., Shah, D. O., & Willcox, M. D. P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121105 · Cited by 111
The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates
VanderBeek, B. L., Bonaffini, S. G., & Ma, L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.07.005 · Cited by 97
Ahmad, I. N., Pandit, J., Sultana, Y., Mishra, A. K., Hazari, P. P., & Aqil, M. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.03.060 · Cited by 100
Thakur, R. R. S., Fallows, S. J., McMillan, H. L., Donnelly, R. F., & Jones, D. S. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12152 · Cited by 93
PROPHYLACTIC ANTIBIOTIC USE AFTER INTRAVITREAL INJECTION: Effect on Endophthalmitis Rate
Bhatt, S. S., Stepien, K. E., & Joshi, K. (2011) · Retina · doi:10.1097/iae.0b013e31820f4b4f · Cited by 95
Targeting Ocular Drug Delivery: An Examination of Local Anatomy and Current Approaches
Dosmar, E., Walsh, J., Doyel, M., Bussett, K., Oladipupo, A., Amer, S., & Goebel, K. (2022) · Bioengineering · doi:10.3390/bioengineering9010041 · Cited by 91
“The researchers determined that the continued use of triamcinolone acetonide injections to the vitreous is an effective treatment for appropriate ocular diseases; however, consistent monitoring for dangerous increases in IOP or the development of cataracts is a necessary precaution that needs to be taken when using su…”
BackgroundMethodInfluentialMicroneedles for enhanced transdermal and intraocular drug delivery
Moffatt, K., Wang, Y., Singh, T. R. R., & Donnelly, R. F. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.007 · Cited by 85
“Additionally, administration with long hypodermic needles via the intravitreal route should firmly adhere to safeguards to protect the lens and retina from mechanical injury [42].”
BackgroundShil, P. K., Kwon, K., Zhu, P., Verma, A., Daniell, H., & Li, Q. (2014) · Molecular Therapy · doi:10.1038/mt.2014.179 · Cited by 88
Gonella, A., Grizot, S., Liu, F., Noriega, A. L., & Richard, J. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2105318 · Cited by 90
FACTORS AFFECTING PATIENTS' PAIN INTENSITY DURING IN OFFICE INTRAVITREAL INJECTION PROCEDURE
Rifkin, L. M., & Schaal, S. (2011) · Retina · doi:10.1097/iae.0b013e3182252ad3 · Cited by 82
Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery
Wang, Q., Zuo, Z., Cheung, C. K. C., & Leung, S. S. Y. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.030 · Cited by 81
“endophthalmitis, retinal detachment, vitreous hemorrhage, cataract (Peyman et al., 2009) and decreased patient compliances.”
BackgroundSadaka, A., Durand, M. L., & Gilmore, M. S. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.03.004 · Cited by 82
“of intravitreal injections for treatment of neovascular eye disease and intraocular inflammation (Peyman et al., 2009).”
The suprachoroidal space: from potential space to a space with potential
Moisseiev, E., Loewenstein, A., & Yiu, G. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s89784 · Cited by 76
“35,36 Intravitreal injections have a good safety profile, but it should be remembered that they can cause ocular complications, including cataract formation, glaucoma, choroidal hemorrhage, endophthalmitis, vitreous hemorrhage, and retinal detachment, 37 and the injected drug can be absorbed and…”
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 78
Osswald, C. R., & Kang‐Mieler, J. J. (2016) · Current Eye Research · doi:10.3109/02713683.2015.1101140 · Cited by 75
An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation
Astley, R., Miller, F. C., Mursalin, M. H., Coburn, P. S., & Callegan, M. C. (2019) · Toxins · doi:10.3390/toxins11060356 · Cited by 87
“Intravitreal injections are also being performed at greater frequencies for the treatment of neovascular eye disease, neurodegenerative diseases, and intraocular inflammation [45].”
BackgroundKang-Mieler, J. J., Dosmar, E., Liu, W., & Mieler, W. F. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227785 · Cited by 73
RANDOMIZED TRIAL OF ANESTHETIC METHODS FOR INTRAVITREAL INJECTIONS
Blaha, G. R., Tilton, E. P., Barouch, F. C., & Marx, J. L. (2010) · Retina · doi:10.1097/iae.0b013e3181eac724 · Cited by 73
Severe bacterial endophthalmitis: towards improving clinical outcomes
Novosad, B. D., & Callegan, M. C. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.52 · Cited by 73
Complications of Intravitreal Injections in Patients with Diabetes
Shikari, H., Silva, P. S., & Sun, J. K. (2014) · Seminars in Ophthalmology · doi:10.3109/08820538.2014.962167 · Cited by 73
“used rabbit vitreous and air to repair retinal detachments in humans.(1) During the late 1960s and early”
BackgroundMethodSouied, E. H., Dugel, P. U., Ferreira, A., Hashmonay, R., Lu, J., & Kelly, S. P. (2016) · Ophthalmic Epidemiology · doi:10.3109/09286586.2015.1090004 · Cited by 65
Chong, D. Y., Anand, R., Williams, P. D., Qureshi, J. A., & Callanan, D. G. (2010) · Retina · doi:10.1097/iae.0b013e3181dc04da · Cited by 66
Intravitreal drug delivery in retinal disease: are we out of our depth?
Thakur, S. S., Barnett, N. L., Donaldson, M. J., & Parekh, H. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927864 · Cited by 62
Giannaccini, M., Giannini, M., Calatayud, M., Goya, G., Cuschieri, A., Dente, L., & Raffa, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15011590 · Cited by 61
“In the first instance, the initial high drug concentration can provoke short term complications such as retinal detachment, endophthalmitis and intravitreal hemorrhages [4].”
BackgroundTargeted and Reversible Blood-Retinal Barrier Disruption via Focused Ultrasound and Microbubbles
Park, J., Zhang, Y., Vykhodtseva, N., Akula, J. D., & McDannold, N. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042754 · Cited by 57
“Intravitreal injections can effectively deliver drugs to the fundus, but this is an unpleasant, invasive procedure with risk of retinal detachment, retinal hemorrhage, endophthalmitis and glaucoma [9,10].”
BackgroundHirani, A., Grover, A., Lee, Y. W., Pathak, Y. V., & Sutariya, V. B. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.965326 · Cited by 60
Xing, L., Dorrepaal, S. J., & Gale, J. S. (2014) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.03.009 · Cited by 59
Thakur, S. S., Shenoy, S., Suk, J. S., Hanes, J. S., & Rupenthal, I. D. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.01.008 · Cited by 56
Posterior Drug Delivery Via Periocular route: Challenges and Opportunities
Waite, D., Wang, Y., Jones, D., Stitt, A., & Raj Singh, T. R. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0097 · Cited by 54
“However, the drugs of lower molecular weight are rapidly eliminated, thereby frequent administration becomes necessary, which in turn leads to an increased chance of problems associated with frequent injections, such as retinal detachment, retinal hemorrhage, and endophthalmitis [25,27].”
BackgroundIntravitreal Injection Technique
Doshi, R. R., Bakri, S. J., & Fung, A. E. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2010.541318 · Cited by 48
Controlled and Extended Release of a Model Protein from a Microsphere-Hydrogel Drug Delivery System
Osswald, C. R., & Kang‐Mieler, J. J. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1314-7 · Cited by 54
Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization
Tavakoli, S., Puranen, J., Bahrpeyma, S., Lautala, V. E., Karumo, S., Lajunen, T., del Amo, E. M., Ruponen, M., & Urtti, A. O. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121725 · Cited by 55
COMPARISON OF TOPICAL ANESTHETICS FOR INTRAVITREAL INJECTIONS
Davis, M. J., Pollack, J. S., & Shott, S. (2012) · Retina · doi:10.1097/iae.0b013e31822f27ca · Cited by 51
Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery
Baskakova, A., Awwad, S., Quirós, J., Gill, H., Novikov, O. O., Khaw, P. T., Brocchini, S., Zhilyakova, E. T., & Williams, G. R. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.015 · Cited by 52
“…delivery of acyclovir is safe and well tolerated by rabbit retina, but its half-life in vivo is short405 (Damico et al., 2012; John, 2007; Peyman et al., 2008).406 407 When the ACY loaded PVP fibers were tested in the PK-Eye, the drug concentration displayed a408 mono-exponential…”
BackgroundInfluentialEvaluation of Pain in Intravitreal Bevacizumab Injections
Moisseiev, E., Regenbogen, M., Bartfeld, Y., & Barak, A. (2012) · Current Eye Research · doi:10.3109/02713683.2012.681335 · Cited by 51
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION
Nentwich, M. M., Yactayo-Miranda, Y., Schwarzbach, F., Wolf, A., Kampik, A., & de Kaspar, H. M. (2013) · Retina · doi:10.1097/iae.0000000000000011 · Cited by 50
Challenges for the pharmaceutical technical development of protein coformulations
Mueller, C., Altenburger, U., & Mohl, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12731 · Cited by 50
Edwards, G., Olson, C. G., Euritt, C. P., & Koulen, P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.890021 · Cited by 54
Modeling intraocular bacterial infections
Astley, R., Coburn, P. S., Parkunan, S. M., & Callegan, M. C. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.007 · Cited by 48
“By directly injecting antibiotics into the vitreous humor, a therapeutic concentration can be more quickly achieved than by administering drugs via other routes such as systemic, topical, or subconjunctival (Baum et al., 1982; Peyman et al., 2009).”
BackgroundLiu, Y., Lin, Y., Lin, Y., Lin, C., Lan, G., Su, Y., Hu, F., Chang, K., Chen, C.-F., Yeh, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202308635 · Cited by 59
Prefilled syringes for intravitreal drug delivery
Sassalos, T. M., & Paulus, Y. M. (2019) · Clinical ophthalmology · doi:10.2147/opth.s169044 · Cited by 45
Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure
Lambert, W. S., Carlson, B. J., van der Ende, A. E., Shih, G. C., Dobish, J. N., Calkins, D. J., & Harth, E. M. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.1.1 · Cited by 43
Kim, Y. C., Edelhauser, H. F., & Prausnitz, M. R. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300696 · Cited by 43
Pershing, S., Bakri, S. J., & Moshfeghi, D. M. (2013) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20130909-07 · Cited by 42
Self-citationDrug discovery in ophthalmology: past success, present challenges, and future opportunities
Gower, N. J. D., Barry, R. J., Edmunds, M. R., Titcomb, L. C., & Denniston, A. K. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0188-2 · Cited by 41
“Despite lowering the risk of systemic exposure to drug their requirement for repeated invasive administration is associated with a significant cumulative risk of complications including retinal detachment, endophthalmitis and increased ocular pressure [88].”
Focused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia
Touahri, Y., Dixit, R., Kofoed, R. H., Miloska, K., Park, E., Raeisossadati, R., Markham-Coultes, K., David, L. A., Rijal, H., Zhao, J., et al. (2020) · Theranostics · doi:10.7150/thno.42611 · Cited by 43
“While intravitreal injections of various AAVs have been demonstrated to successfully target Müller glia [25, 26], bypassing the inner limiting membrane, given the potential for damage with this delivery route, we asked whether FUS could be used as a less invasive strategy to target this cell…”
Pelusi, L., Mandatori, D., Mastropasqua, L., Agnifili, L., Allegretti, M., Nubile, M., & Pandolfi, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020625 · Cited by 41
Wang, S., Wang, B., Feng, Y., Mo, M., Du, F., Li, H., & Yu, X. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0384-6 · Cited by 39
“The advantage of the IVI technique is its ability to maximize the intraocular levels of medications (Peyman et al. 2009), whereas elevated intraocular pressure and glaucoma are the most common side effects (Jonas et al.”
BackgroundCritical Assessment of Implantable Drug Delivery Devices in Glaucoma Management
Manickavasagam, D., & Oyewumi, M. O. (2013) · Journal of Drug Delivery · doi:10.1155/2013/895013 · Cited by 43
“Further, repeated administration via this route could lead to ocular complications such as retinal detachment, vitreous hemorrhage, irritation, and infection at the implantation site [9, 77].”
BackgroundGene therapy for ocular diseases meditated by ultrasound and microbubbles (Review)
WAN, C., LI, F., & LI, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4054 · Cited by 36
“Though sub-retinal and intravitreal injections can provide direct access for genes to the retina, these invasive methods are not the first choice for the treatment of the diseases of the eye due to the risk of the retinal detachment and hemorrhage (20).”
Patel, S. P., Vaishya, R. D., Mishra, G. P., Tamboli, V., Pal, D., & Mitra, A. K. (2014) · Journal of Drug Delivery · doi:10.1155/2014/401747 · Cited by 36
Güler, M., Bilgin, B., Çapkın, M., Şimşek, A., & Bilak, Ş. (2015) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2015.29.3.190 · Cited by 34
“ists and become one of the most common intraocular procedures [5].”
BackgroundCationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors
Cotto, H. A. M., Pathrikar, T. V., Hakim, B., Baby, H. M., Zhang, H., Zhao, P., Ansaripour, R., Amini, R., Carrier, R. L., & Bajpayee, A. G. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00849a · Cited by 33
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach
Petri, A.-S., Boysen, K. B., Cehofski, L. J., van Dijk, E. H. C., Dysli, C., Fuchs, J., Mastropasqua, R., & Subhi, Y. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00230-4 · Cited by 35
Lin, T., Hung, K.-H., Peng, C., Liu, J., Woung, L., Tsai, C., Chen, S., Chen, Y., & Hsu, C. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2015.07.008 · Cited by 32
Novel Pentablock Copolymer-Based Nanoparticulate Systems for Sustained Protein Delivery
Patel, S. P., Vaishya, R. D., Pal, D., & Mitra, A. K. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0196-6 · Cited by 36
van Asten, F., van Middendorp, H., Verkerk, S., Breukink, M. B., Lomme, R. M. L. M., Hoyng, C. B., Evers, A. W. M., & Klevering, B. J. (2015) · Retina · doi:10.1097/iae.0000000000000550 · Cited by 37
Yu, J., Yin, Y., Leng, Y., Zhang, J., Wang, C., Chen, Y., Li, X., Wang, X., Liu, H., Liao, Y., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114842 · Cited by 31
Pierdomenico, J. D., García‐Ayuso, D., Jiménez-López, M., Agudo‐Barriuso, M., Vidal‐Sanz, M., & Villegas‐Pérez, M. P. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19618 · Cited by 32
Povidone-Iodine Before Lidocaine Gel Anesthesia Achieves Surface Antisepsis
Doshi, R. R., Leng, T., & Fung, A. E. (2011) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20110210-02 · Cited by 29
Declining Incidence of Neonatal Endophthalmitis in the United States
Moshfeghi, A. A., Charalel, R. A., Hernandez‐Boussard, T., Morton, J. M., & Moshfeghi, D. M. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.07.008 · Cited by 28
Self-citationFuchs, H., & Igney, F. H. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0083 · Cited by 28
“Due to the invasiveness of the injection, the associated risk, and discomfort for the patient, the dosing frequency should be as low as possible and once monthly IVT administration is considered as the maximum dosing frequency for chronic treatment (for review see Peyman et al.(1)).”
Nanotechnology for ocular drug delivery
Agarwal, P., Huang, D., Thakur, S. S., & Rupenthal, I. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00004-8 · Cited by 30
Yadav, D., Varma, L. T., & Yadav, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_3 · Cited by 27
Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems
Baino, F., & Kargozar, S. (2020) · Bioengineering · doi:10.3390/bioengineering7030065 · Cited by 29
“For this reason, serious complications are possible, including cataracts, vitreous hemorrhage, retinal detachment, and endophthalmitis [33].”
BackgroundNejad, M. M., Bardania, H., Aliakbari, F., Baradaran‐Rafii, A., Elahi, E., Monti, D., & Morshedi, D. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119895 · Cited by 30
Mathematical Models of Ocular Drug Delivery
Sadeghi, A., Subrizi, A., del Amo, E. M., & Urtti, A. O. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.11.28 · Cited by 30
“67 Thus, higher retinal bioavailability is achieved for small molecule drugs (e.g. corticosteroids and antibiotics), 69,70 and macro-molecules (anti-VEGF antibodies, Fab-fragments, and soluble receptors).”
BackgroundPatel, S. P., Vaishya, R. D., Yang, X., Pal, D., & Mitra, A. K. (2014) · Protein and Peptide Letters · doi:10.2174/092986652111141001122054 · Cited by 27
Advances in biomaterials for the treatment of retinoblastoma
Farhat, W., Yeung, V., Ross, A., Kahale, F., Boychev, N., Kuang, L., Chen, L., & Ciolino, J. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01005d · Cited by 29
TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION
Ulrich, J. N. (2013) · Retina · doi:10.1097/iae.0b013e3182a0e611 · Cited by 26
Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System
Rudeen, K. M., Liu, W., Mieler, W. F., & Kang‐Mieler, J. J. (2022) · Current Eye Research · doi:10.1080/02713683.2022.2053166 · Cited by 25
“The known risks of complications associated with repeated IVT injections include retinal detachment, endophthalmitis, IVT hemorrhage, and cataract.(4,5) Additionally, the frequency of treatment places a significant burden on patients and healthcare systems.”
BackgroundMénochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 30
Mushtaq, Y., Mushtaq, M., Gatzioufas, Z., Ripa, M., Motta, L., & Panos, G. D. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s403259 · Cited by 25
Kim, K. H., Cao, J., Yoo, J., Yoon, I., Jung, J. W., Lee, J. E., & Byon, I. S. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17739 · Cited by 27
Amato, R., Monte, M. D., Lulli, M., Raffa, V., & Casini, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170717115654 · Cited by 25
“Thus, the increase of administration frequency could lead to eye tissue damage and iatrogenic infections [14].”
BackgroundPark, S. W., Kim, J. H., Park, W. J., & Kim, J. H. (2015) · Journal of Visualized Experiments · doi:10.3791/53030 · Cited by 26
Moisseiev, E., Rudell, J. C., Tieu, E., & Yiu, G. C. (2017) · Current Eye Research · doi:10.1080/02713683.2016.1276195 · Cited by 24
Acute sterile endophthalmitis following intravitreal bevacizumab: case series
Vélez-Montoya, R., Ortega-Larrocea, X., Orozco‐Hernández, A., Sánchez-Bermúdez, G., Morales-Cantón, V., & García‐Aguirre, G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s66230 · Cited by 25
Patel, S. P., Vaishya, R., Patel, A., Agrahari, V., Pal, D., & Mitra, A. K. (2016) · Journal of Microencapsulation · doi:10.3109/02652048.2015.1134685 · Cited by 23
“Such frequent injections are inconvenient and can cause many other complications such as secondary infections (endophthalmitis), retinal detachment, retinal haemorrhage and patient non-compliance (Jager et al., 2004; Peyman et al., 2009; Sampat and Garg, 2010).”
BackgroundAge-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies
Lorenzo-Veiga, B., Alvarez‐Lorenzo, C., Loftsson, Þ., & Sigurðsson, H. H. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120707 · Cited by 24
Chen, R. W. S., Rachitskaya, A. V., Scott, I. U., & Flynn, H. W. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2524 · Cited by 23
Effect of Lidocaine Gel Anesthesia on Endophthalmitis Rates Following Intravitreal Injection
Lad, E. M., Maltenfort, M., & Leng, T. (2012) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20120119-01 · Cited by 22
Self-citationKim, M.-J., Kim, J. Y., Rhim, W.-K., Cimaglia, G., Want, A., Morgan, J. E., Williams, P. A., Park, C. G., Han, D. K., & Rho, S. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01777-0 · Cited by 21
“Intravitreal injections are an efficient method for delivering drugs into the retina and are currently a widely utilised modality in many retinal diseases [74].”
Method
Metadata
- Authors
- PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M.
- Affiliations
- University of Arizona (US)
- Stanford University (US)
- Corresponding author
- PEYMAN, GHOLAM A.
- Venue
- Retina
- Published
- 2009-07
- Volume
- 29
- Issue
- 7
- Pages
- 875-912
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2090780299
- Cited by
- 255
- References
- 536
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 19 · 2016: 24 · 2015: 16 · 2014: 18 · 2013: 11 · 2012: 20
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- intravitreal injection, endophthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, retinal detachment, VEGF inhibitors, anti-inflammatory agents, immunomodulators, anticancer agents, gas tamponade, injection complications
- MeSH terms
- Drug Therapy, Humans, Injections, Vitreous Body
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.